This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (129)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Complementary and Alternative Medicine  • Quality of Care  • Evidence-Based Medicine  • Sports Medicine  • Review  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

A Meta-analysis

Paul G. Shekelle, MD, PhD; Mary L. Hardy, MD; Sally C. Morton, PhD; Margaret Maglione, MPP; Walter A. Mojica, MD, MPH; Marika J. Suttorp, MS; Shannon L. Rhodes, MFA; Lara Jungvig, BA; James Gagné, MD

JAMA. 2003;289:1537-1545.

Context  Ephedra and ephedrine sometimes are used for weight loss or enhanced athletic performance, but the efficacy and safety of these compounds are uncertain.

Objective  To assess the efficacy and safety of ephedra and ephedrine used for weight loss and enhanced athletic performance.

Data Sources  We searched 9 databases using the terms ephedra, ephedrine, adverse effect, side effect, efficacy, effective, and toxic. We included unpublished trials and non–English-language documents. Adverse events reported to the US Food and Drug Administration MedWatch program were assessed.

Study Selection  Eligible studies were controlled trials of ephedra or ephedrine used for weight loss or athletic performance and case reports of adverse events associated with such use. Eligible studies for weight loss were human studies with at least 8 weeks of follow-up; and for athletic performance, those having no minimum follow-up. Eligible case reports documented that ephedra or ephedrine was consumed within 24 hours prior to an adverse event or that ephedrine or an associated product was found in blood or urine, and that other potential causes had been excluded. Of the 530 articles screened, 52 controlled trials and 65 case reports were included in the adverse events analysis. Of more than 18 000 other case reports screened, 284 underwent detailed review.

Data Extraction  Two reviewers independently identified trials of efficacy and safety of ephedra and ephedrine on weight loss or athletic performance; disagreements were resolved by consensus. Case reports were reviewed with explicit and implicit methods.

Data Synthesis  No weight loss trials assessed duration of treatment greater than 6 months. Pooled results for trials comparing placebo with ephedrine (n = 5), ephedrine and caffeine (n = 12), ephedra (n = 1), and ephedra and herbs containing caffeine (n = 4) yielded estimates of weight loss (more than placebo) of 0.6 (95% confidence interval, 0.2-1.0), 1.0 (0.7-1.3), 0.8 (0.4-1.2), and 1.0 (0.6-1.3) kg/mo, respectively. Sensitivity analyses did not substantially alter the latter 3 results. No trials of ephedra and athletic performance were found; 7 trials of ephedrine were too heterogeneous to synthesize. Safety data from 50 trials yielded estimates of 2.2- to 3.6-fold increases in odds of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations. Data are insufficient to draw conclusions about adverse events occurring at a rate less than 1.0 per thousand. The majority of case reports are insufficiently documented to allow meaningful assessment.

Conclusions  Ephedrine and ephedra promote modest short-term weight loss (0.9 kg/mo more than placebo) in clinical trials. There are no data regarding long-term weight loss, and evidence to support use of ephedra for athletic performance is insufficient. Use of ephedra or ephedrine and caffeine is associated with increased risk of psychiatric, autonomic, or gastrointestinal symptoms, and heart palpitations.

Author Affiliations: Southern California Evidence-based Practice Center–RAND, Santa Monica, Calif (Drs Shekelle, Morton, Mojica, and Mss Maglione, Suttorp, Rhodes, and Jungvig); Cedars-Sinai Medical Center, Los Angeles, Calif (Dr Hardy); Greater Los Angeles Veterans Affairs Healthcare System (Dr Shekelle); and Department of Family Medicine, University of Southern California, Los Angeles (Dr Gagné).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

The Need for Regulation of Dietary Supplements—Lessons From Ephedra
Phil B. Fontanarosa, Drummond Rennie, and Catherine D. DeAngelis
JAMA. 2003;289(12):1568-1570.
EXTRACT | FULL TEXT  

Ephedra and Ephedrine
Janet M. Torpy, Cassio Lynm, and Richard M. Glass
JAMA. 2003;289(12):1590.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Should weight-loss supplements be used for pediatric obesity?
Rogovik and Goldman
cfp 2009;55:257-259.
ABSTRACT | FULL TEXT  

Current pharmacotherapeutic concepts for the treatment of obesity in adults
Idelevich et al.
Ther Adv Cardiovasc Dis 2009;3:75-90.
ABSTRACT  

Use of a Prescribed Ephedrine/Caffeine Combination and the Risk of Serious Cardiovascular Events: A Registry-based Case-Crossover Study
Hallas et al.
Am J Epidemiol 2008;168:966-973.
ABSTRACT | FULL TEXT  

Pharmacological Treatment of the Overweight Patient
Bray and Greenway
Pharmacol. Rev. 2007;59:151-184.
FULL TEXT  

Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea
Diepvens et al.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007;292:R77-R85.
ABSTRACT | FULL TEXT  

Water-Induced Thermogenesis Reconsidered: The Effects of Osmolality and Water Temperature on Energy Expenditure after Drinking
Brown et al.
J. Clin. Endocrinol. Metab. 2006;91:3598-3602.
ABSTRACT | FULL TEXT  

Dietary Supplements: Reports Reviewed by Tia Powell and Barbara A. Noah: Institute of Medicine, Dietary Supplements: A Framework for Evaluating Safety (Washington, D.C., 2005).
J Law Med Ethics 2005;33:857-865.
 

Cardiovascular Toxicities of Performance-Enhancing Substances in Sports
Dhar et al.
Mayo Clin Proc. 2005;80:1307-1315.
ABSTRACT  

Dietary supplement-related adverse events reported to the California Poison Control System
Dennehy et al.
Am J Health Syst Pharm 2005;62:1476-1482.
ABSTRACT | FULL TEXT  

Integrating Complementary Medicine Into Cardiovascular Medicine: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine)
Vogel et al.
J Am Coll Cardiol 2005;46:184-221.
FULL TEXT  

Challenges in Systematic Reviews of Complementary and Alternative Medicine Topics
Shekelle et al.
ANN INTERN MED 2005;142:1042-1047.
ABSTRACT | FULL TEXT  

Ephedrine plus caffeine causes age-dependent cardiovascular responses in Fischer 344 rats
Howden et al.
Am. J. Physiol. Heart Circ. Physiol. 2005;288:H2219-H2224.
ABSTRACT | FULL TEXT  

Thyrotoxicosis Caused by Weight-Reducing Herbal Medicines
Ohye et al.
Arch Intern Med 2005;165:831-834.
ABSTRACT | FULL TEXT  

Psychiatric Effects of Ephedra Use: An Analysis of Food and Drug Administration Reports of Adverse Events
Maglione et al.
Am. J. Psychiatry 2005;162:189-191.
ABSTRACT | FULL TEXT  

Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease: A Statement for Professionals From the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: Endorsed by the American College of Cardiology Foundation
Klein et al.
Circulation 2004;110:2952-2967.
ABSTRACT | FULL TEXT  

Dietary Supplements: Policy and Research Implications for Nurses
Xue and Cohen
Policy Politics Nursing Practice 2004;5:149-159.
ABSTRACT  

The ABC Clinical Guide to Herbs: edited by Mark Blumenthal, 2003, 480 pages, hardcover, $69.95. American Botanical Council, Austin, TX.
Halsted
Am. J. Clin. Nutr. 2004;79:1127-1128.
FULL TEXT  

More Evidence Supporting the Ban of Ephedra Dietary Supplements
Chavez
The Annals of Pharmacotherapy 2004;38:895-897.
FULL TEXT  

Herbal Weight-Loss Supplement Misadventures Per a Regional Poison Center
Robinson et al.
The Annals of Pharmacotherapy 2004;38:787-790.
ABSTRACT | FULL TEXT  

Physicians' Personal Intake and Prescription of Weight Loss Products: Are We Practicing What We Preach?
La Puma et al.
Arch Intern Med 2004;164:806-807.
FULL TEXT  

Cardiovascular Effects of Ephedra
Ness
JAMA 2004;291:1560-1560.
FULL TEXT  

Dietary supplements for body-weight reduction: a systematic review
Pittler and Ernst
Am. J. Clin. Nutr. 2004;79:529-536.
ABSTRACT | FULL TEXT  

Regulation of Dietary Supplements--Reply
DeAngelis and Fontanarosa
JAMA 2004;291:560-560.
FULL TEXT  

Electrocardiographic and Hemodynamic Effects of a Multicomponent Dietary Supplement Containing Ephedra and Caffeine: A Randomized Controlled Trial
McBride et al.
JAMA 2004;291:216-221.
ABSTRACT | FULL TEXT  

OTHER ARTICLES NOTED (25 Apr 2003 to 18 Jul 2003)
Evid. Based Nurs. 2003;6:e1-12.
FULL TEXT  

Drugs Alias Dietary Supplements
DeAngelis and Fontanarosa
JAMA 2003;290:1519-1520.
FULL TEXT  

The Relative Safety of Ephedra Compared with Other Herbal Products
Kimmel
ANN INTERN MED 2003;139:234-234.
FULL TEXT  

The Relative Safety of Ephedra Compared with Other Herbal Products
Bent et al.
ANN INTERN MED 2003;138:1006-1007.
FULL TEXT  

Ephedrine for Weight Loss and Athletic Performance -- Not Effective, Possibly Dangerous
Journal Watch Dermatology 2003;2003:11-11.
FULL TEXT  

Safety and Efficacy of Ephedra and Ephedrine Still Unsettled
JWatch Emergency Med. 2003;2003:7-7.
FULL TEXT  

Ephedrine for Weight Loss and Athletic Performance -- Not Effective, Possibly Dangerous
JWatch Psychiatry 2003;2003:8-8.
FULL TEXT  

Ephedra: Substantial Risk, Little Benefit
Journal Watch Cardiology 2003;2003:3-3.
FULL TEXT  

Risks of Ephedra and Ephedrine
JWatch Pediatrics 2003;2003:1-1.
FULL TEXT  

Rosack
Psychiatr. News 2003;38:46-47.
FULL TEXT  

Ephedrine for Weight Loss and Athletic Performance -- Not Effective, Possibly Dangerous
JWatch General 2003;2003:6-6.
FULL TEXT  

The Need for Regulation of Dietary Supplements--Lessons From Ephedra
Fontanarosa et al.
JAMA 2003;289:1568-1570.
FULL TEXT